Michael Pellini is a General Partner at S32, where the firm's team page lists him as Mike Pellini, MD; he joined in 2017, when the firm was named Section 32. He was CEO and then chairman of Foundation Medicine through the close of Roche's acquisition in August 2018, and before that president and chief operating officer of Clarient, which GE Healthcare acquired in 2010. He serves on the boards of Nusano and Exai Bio, and was the S32 partner named in the March 2024 announcement of the firm's $33 million Series C financing of Brightside Health. He holds an M.D. from Jefferson Medical College, an M.B.A. from Drexel University and a B.A. from Boston College.
Education
M.D., Jefferson Medical College
M.B.A., Drexel University
B.A., Boston College
Previous Experience
President and COO, Clarient (acquired by GE Healthcare in 2010)
CEO and then Chairman, Foundation Medicine (acquired by Roche in 2018)